VGXI will support expedited development and scale-up of multiple vaccine candidates to treat Ebola through a DARPA funded collaboration.
US Congressman Kevin Brady will be visiting the VGXI manufacturing facility in The Woodlands, TX to take a tour of the production plant and provide a statement on the impact of this work and the DNA-based therapeutics being produced at VGXI. Leadership from Inovio Pharmaceuticals and GeneOne Life Sciences will also be present to provide a brief overview of the collaboration and the scope of the DARPA funded project.
How these therapies are different from many other Ebola vaccines in development:
- The vaccine contains DNA only – no virus particles or proteins will be manufactured
- The vaccine can be used to treat to patients who have already been exposed to the virus
- DNA vaccine production can be scaled-up very rapidly in case of an outbreak
Full details of the DARPA funding and development of new treatments for Ebola can be found in the following press release:
Inovio Pharmaceuticals Selected by DARPA to Lead a $45 Million Program to Expedite Development of Novel Products to Prevent and Treat Disease Caused by Ebola